Picone Carmine, Porto Annamaria, Fusco Roberta, Granata Vincenza, Brunese Maria Chiara, Montanino Agnese, Esposito Giovanna, Costanzo Raffaele, Manzo Anna, Sforza Vincenzo, Sandomenico Claudia, Palumbo Giuliano, Mercadante Edoardo, Ottaiano Alessandro, Vallone Gianfranco, Caranci Ferdinando, Mormile Raffaella, Morabito Alessandro, Petrillo Antonella
Radiology Division, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, Napoli, Italy.
Radiology Division, Università degli Studi del Molise, Campobasso, Italy.
Cancer Control. 2025 Jan-Dec;32:10732748241301901. doi: 10.1177/10732748241301901. Epub 2025 Mar 16.
Malignant pleural mesothelioma is the most common primary tumor of the pleura. The unique growth pattern of malignant pleural mesothelioma makes it difficult to apply the Response Evaluation Criteria for Solid Tumors (RECIST). Hence the need to use modified RECIST (mRECIST) criteria, as they better fit the unique growth pattern of malignant pleural mesothelioma. The thickness of the tumor perpendicular to the chest wall or mediastinum is measured at 2 points at 3 separate levels at least 1 cm apart on chest CT scans, and summed to obtain a one-dimensional pleural measurement. The same criterion has also been used to assess response to treatment. RECIST 1.1 represents a further update, taking into account new concepts such as revised minimum dimensions for lymph nodes and an approach to lesions that become non-measurable. Based on experience and published literature, the hypothesis of merging the 2 above-mentioned criteria in mRECIST 1.1 for mesothelioma and the use of iRECIST for the application to immune-based therapies (iRECIST) was considered. Support the importance of studying pleural mesothelioma in a reliable and reproducible way, through a scrupulous methodology, applying the mRECIST1.1 and iRECIST criteria. Adoption of a standardized study metodology can make the study of PM reproducible and correct.
恶性胸膜间皮瘤是最常见的胸膜原发性肿瘤。恶性胸膜间皮瘤独特的生长模式使得应用实体瘤疗效评价标准(RECIST)变得困难。因此需要使用改良的RECIST(mRECIST)标准,因为它们更符合恶性胸膜间皮瘤独特的生长模式。在胸部CT扫描上,在至少相隔1厘米的3个不同层面上的2个点测量肿瘤垂直于胸壁或纵隔的厚度,并将其相加以获得一维胸膜测量值。相同的标准也用于评估治疗反应。RECIST 1.1是进一步的更新,考虑了诸如修订后的淋巴结最小尺寸以及对不可测量病变的处理方法等新概念。基于经验和已发表的文献,考虑了在用于间皮瘤的mRECIST 1.1中合并上述两个标准以及将iRECIST用于基于免疫的疗法(iRECIST)的假设。通过严谨的方法,应用mRECIST1.1和iRECIST标准,支持以可靠且可重复的方式研究胸膜间皮瘤的重要性。采用标准化的研究方法可以使胸膜间皮瘤的研究具有可重复性和正确性。